PITTSBURGH, Feb. 17, 2012 /PRNewswire/ -- Mylan Inc. today announced that the company and its subsidiary, Mylan Pharmaceuticals Inc., have resolved the defamation and other related litigation filed by Mylan against the Pittsburgh Post-Gazette and two of its reporters. In connection with the resolution, the parties have agreed to the following statement:
"The litigation has been resolved to the satisfaction of both parties. The Post-Gazette did not find and did not intend to report that Mylan had manufactured or distributed any defective drugs. The Post-Gazette regrets if any reader of the article thought otherwise."
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com.
SOURCE Mylan Inc.